Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophageal Cancer Patients

Dr. Rick Greene and Dr. Basem Azab discuss the relationship of the interval between neoadjuvant chemoradiation-to-surgery in the treatment of esophageal cancer, and associated pathological complete response rate and overall survival rate. Dr. Azab is author of the Annals of Surgical Oncology article “Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophageal Cancer Patients.” Dr. Azab is a surgical oncology specialist at Sentara Healthcare, Newport News, VA.  His clinical expertise includes but is not limited to Esophageal Cancer, Endocrine Tumors, Gastrointestinal Oncology, Hepatobiliary Tumors.